Catch up on all the action-packed sessions at your convenience without missing the expert advice and educational content. Elevate your understanding of patient-centric care and equip yourself with actionable business strategies through expert-led sessions.
Turning Food Allergy Triggers Into Therapy: A Managed Care Lens on Immunotherapy and Targeted Biologics
1.5 Credits / Immunology
View More
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacy Technician Credi...
2.0 Credits / HIV/AIDS
View More
Navigating Approved Pre-exposure Prophylaxis (PrEP) Options for HIV Prevention: The Expanding Role of Pharmacists as Patient Educators and Advocates (Pharmacist Credit)
2.0 Credits / HIV/AIDS
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team
1.5 Credits / Hematology, Oncology
View More
Navigating Long-Term Toxicities of CAR T-Cell Therapy: Educational Insights for Oncology Pharmacists
May 14, 2024 | 7:00 PM ET
View More
Mastering Immunotherapy-Based Approaches in Advanced Endometrial Cancer: A Pharmacist’s Perspective
May 15, 2024 | 7:00 PM ET
View More
Overview of Paroxysmal Nocturnal Hemoglobinuria: Pathophysiology of the Complement Pathway and Clinical and Economic Burden
May 16, 2024 | 1:00 & 6:00 PM ET
View More
FDA Approves Second Formulation of Humira Biosimilar Cyltezo
May 1st 2024According to Michael Osso, president and chief executive officer of the Crohn’s & Colitis Foundation, “the flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicine.”
Navigating Ethical, Financial Considerations When Delivering Cancer Care
April 30th 2024“I think in those situations where you can use the lower cost of the drug, you should, because it's going to help the overall societal perspective. That begins to break down, though, when that low-cost drug is the one that you're losing money on,” said Scott Soefje in a Q&A on balancing cost and margin at a site of care.